The Power of Networks: Why Rare Diseases Demand Collaboration
Senior moderator Leigh Hart explores the role of pharmaceutical companies in the Rare Disease Networks, what was planned and how it has worked out. Rare
Senior moderator Leigh Hart explores the role of pharmaceutical companies in the Rare Disease Networks, what was planned and how it has worked out. Rare
Erin Paterson shares her experience of being gene positive for the rare Huntington disease, and how she is on a mission to positively impact other
Our Research Consultant Andrew Grant advocates for awareness of the physical and mental issues patients face while their condition remains undiagnosed Getting a diagnosis when
LDA Research is supporting CureLONP1.com Aria’s Miracle research fund and her parent’s conviction that hope lies within the global medical and scientific community Aria’s parents need to
LDA Research talks to Rare Disease Girl Taylor Coffman, about action and advocacy for patients worldwide with rare diseases, in support of Rare Disease Day
Why is Patient Feedback Critical to Rare Disease Treatments? LDA Research are experts at locating and recruiting hard-to-reach patients. Call 01525 861436
Why LDA Research goes the extra mile to locate rare disease specialists. Global research provider for the pharma and medical device sectors.
Uncover the impact of community on your rare disease journey. Our blog post delves into the significance of shared experiences and how our online platforms fosters connection and empowerment.
LDA Research spoke to Sickle Cell Disease patient leader Alidor Gaspar about the quality of care he has received in a society that doesn’t see invisible pain, and the urgent need for blood donations, in support of World Sickle Cell Day
David Napier shares his journey with LDA Research advocating the need for more medical research into Stiff-Person Syndrome (SPS)
LDA Research consultant, Andrew Grant, highlights the shared common experiences of rare disease patients discussed in our Rare Together podcasts
Today, Dr. David Fajgenbaum celebrates being in remission for ten and a half years from the rare Castleman disease. LDA Research’s director Lucy Doorbar talks to him about how he discovered a treatment for his disease, and the importance for pharmaceutical companies to understand the patient experience.